Author

N. B. Green

Observed names: N. Green, N.B. Green

Institution: Southeast Nebraska Cancer Center

Observed institutions: Dartmouth–Hitchcock Medical Center, Mayo Clinic, The Netherlands Cancer Institute, Missouri Valley Cancer Consortium, Southeast Nebraska Cancer Center, Clearview Cancer Institute, Illinois CancerCare, Dartmouth Health

OpenAlex ID: A5023316362

A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA

2009 · D. L. Barton, E. Wos, et al. · Journal of Clinical Oncology · 8

Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA

2009 · S. L. Wolf, R. Qin, et al. · Journal of Clinical Oncology · 4

PD4-1-5: Docetaxel, carboplatin and thoracic radiotherapy in unresectable stage III non-small cell lung cancer (NSCLS): A safety report of the first 100 patients treated with this concurrent chemoradiation as part of a multicenter web-based trial, D0410

2007 · James R. Rigas, M.S. Rubin, et al. · Journal of Thoracic Oncology · 2

Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients

2014 · A. Furay, L.T. Nordquist, et al. · International Journal of Radiation Oncology*Biology*Physics

Safety assessment for the combination of docetaxel, carboplatin, and thoracic radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC): A report of the first 100 patients treated with chemoradiation on D0410

2007 · J. R. Rigas, M. S. Rubin, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 14

H-index: 2

I10-index: